Organon & Co. (NYSE:OGN) Shares Bought by Nia Impact Advisors LLC

Nia Impact Advisors LLC grew its holdings in Organon & Co. (NYSE:OGN - Free Report) by 21.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 223,157 shares of the company's stock after acquiring an additional 38,654 shares during the quarter. Nia Impact Advisors LLC owned 0.09% of Organon & Co. worth $3,330,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Horizon Bancorp Inc. IN boosted its holdings in Organon & Co. by 2,401.5% in the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company's stock worth $25,000 after acquiring an additional 1,585 shares in the last quarter. Millstone Evans Group LLC acquired a new stake in Organon & Co. in the fourth quarter worth about $29,000. Larson Financial Group LLC boosted its holdings in Organon & Co. by 345.4% in the fourth quarter. Larson Financial Group LLC now owns 2,236 shares of the company's stock worth $33,000 after acquiring an additional 1,734 shares in the last quarter. Riverview Trust Co boosted its holdings in Organon & Co. by 117.7% in the fourth quarter. Riverview Trust Co now owns 2,390 shares of the company's stock worth $36,000 after acquiring an additional 1,292 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB boosted its holdings in Organon & Co. by 32.4% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company's stock worth $41,000 after acquiring an additional 672 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company's stock.

Organon & Co. Stock Performance

OGN stock traded up $0.25 during trading on Friday, hitting $9.02. 4,964,443 shares of the company traded hands, compared to its average volume of 3,162,040. The stock's 50-day simple moving average is $12.21 and its 200 day simple moving average is $14.36. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The company has a market cap of $2.35 billion, a PE ratio of 2.71, a P/E/G ratio of 0.90 and a beta of 0.75. Organon & Co. has a 1 year low of $8.01 and a 1 year high of $23.10.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.13. The company had revenue of $1.51 billion during the quarter, compared to analysts' expectations of $1.53 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. Organon & Co.'s quarterly revenue was down 6.7% on a year-over-year basis. During the same period last year, the business earned $1.22 earnings per share. On average, equities analysts expect that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 12th. Investors of record on Monday, May 12th will be given a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a yield of 0.89%. The ex-dividend date is Monday, May 12th. Organon & Co.'s dividend payout ratio is currently 2.78%.

Insider Activity at Organon & Co.

In related news, CFO Matthew M. Walsh purchased 11,400 shares of Organon & Co. stock in a transaction that occurred on Monday, May 5th. The stock was bought at an average cost of $8.82 per share, for a total transaction of $100,548.00. Following the completion of the transaction, the chief financial officer now owns 144,484 shares in the company, valued at $1,274,348.88. The trade was a 8.57% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Kevin Ali purchased 34,000 shares of Organon & Co. stock in a transaction that occurred on Monday, May 5th. The shares were bought at an average price of $8.80 per share, with a total value of $299,200.00. Following the completion of the transaction, the chief executive officer now owns 282,731 shares of the company's stock, valued at $2,488,032.80. This represents a 13.67% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 102,345 shares of company stock worth $902,430. 1.96% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have weighed in on OGN shares. Morgan Stanley lowered their price target on Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating for the company in a report on Monday, May 5th. Piper Sandler reduced their price objective on Organon & Co. from $24.00 to $18.00 and set an "overweight" rating for the company in a research note on Thursday. Evercore ISI cut Organon & Co. from an "outperform" rating to an "inline" rating in a research note on Friday, May 2nd. Finally, Barclays reduced their price objective on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $18.00.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.